Proposal for establishment of a UK post-marketing surveillance registry to study the effectiveness, safety and prescribing habits of tocilizumab for the treatment of giant cell arteritis in the UK National Health Service, nested within the existing structure of the UK GCA Consortium and UKIVAS studies (TARGET)

ENCePP Code of conduct

No

Data sources

• Data sources (types):
  Disease registry

  Other
• Data sources (types), other:
  Prospective patient-based data collection

Use of a Common Data Model (CDM)

• CDM mapping:
  No

Data quality specifications

• Check conformance:
  Unknown
• Check completeness:
  Unknown
• Check stability:
  Unknown
• Check logical consistency:
  Unknown

Data characterisation

• Data characterisation conducted:
  No